



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|----------------------|------------------|
| 10/696,389 | 10/29/2003 | Lawrence T. Boni | TRA-00801 | 6398 |
| 25181 | 7590 | 06/30/2008 | EXAMINER | |
| FOLEY HOAG, LLP PATENT GROUP, WORLD TRADE CENTER WEST 155 SEAPORT BLVD BOSTON, MA 02110 | | | KISHORE, GOLLAMUDI S | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 1612 | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 06/30/2008 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|--------------------------|---|------------------------------------|--|
| Interview Summary | Application No. 10/696,389 | Applicant(s) BONI ET AL. | |
| | Examiner Gollamudi S. Kishore, Ph.D | Art Unit 1612 | |

All participants (applicant, applicant's representative, PTO personnel):

- (1) Gollamudi S. Kishore, Ph.D. (3) Beth Arnold
(2) Dr. Hilary Dorr Lang. (4) Dr. Walter Perkins.

Date of Interview: 25 June 2008.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: proposed claim reciting amikacin.

Identification of prior art discussed: Pror art on record.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Dr. Perkins discussed the ability of the neutral liposomes in penetrating cystic fibrosis mucus as opposed to cationic or anionic liposomes. Based on these discussions, the examiner suggested the introduction of cystic fibrosis in the independent claims and submit the unexpected results in the form a declaration. The allowability of the claims will be determined based the declaration.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Gollamudi S Kishore, Ph.D/
Primary Examiner, Art Unit 1612

Examiner's signature, if required

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.